ArticleBMC microbiology2026
Pathogenic signatures and therapeutic evaluation of emergent MPXV Clade Ib in low-susceptibility and immunocompromised mouse models.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMonkeypox (Mpox) is a zoonotic disease that threatens global public health. Different clades of monkeypox virus (MPXV) vary in transmissibility and pathogenicity. In 2023, a Clade Ib MPXV variant emerged in the Democratic Republic of the Congo, continued to spread in parts of Africa, and subsequently spilled over to other regions, posing new challenges for outbreak prevention and control.
resultsWe established stable mouse models of MPXV Clade Ib infection by intranasally infecting C57BL/6/STAT1
conclusionWe established reproducible mouse models for MPXV Clade Ib infection and demonstrated that Clade Ib showed greater replication capacity and pathogenicity than Clade IIb in these models. This study also provides a foundation for subsequent research on the pathogenesis of MPXV and the evaluation of antiviral efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.